MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2016 International Congress

    Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay

    I. Amorín, A. Lescano, N. Ramírez, V. Raggio, R. Buzó (Montevideo, Uruguay)

    Objective: To know the consumption habits of Yerba Mate in a population of Parkinson's disease (PD) patients from Uruguay. To compare the consumption habits of…
  • 2016 International Congress

    Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

    B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

    Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…
  • 2016 International Congress

    Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein

    Z. Alexopoulou, J. Lang, R. Perrett, H.T. Kim, A.L. Goldberg, O. Ansorge, T.A. Fulga, G.K. Tofaris (Oxford, United Kingdom)

    Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…
  • 2016 International Congress

    Risk factors for premature withdraw from the LS-1 PD study

    J.Y. Fang, S. Luo, M. Huang, R.B. Dewey, R. Hauser, G. Chen (Nashville, TN, USA)

    Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…
  • 2016 International Congress

    Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

    Objective: To identify a new therapeutic target for developing neuroprotective treatment in Parkinson's disease (PD) by improving mitochondrial function through restoration of mitochondrial quality control…
  • 2016 International Congress

    Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

    I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)

    Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…
  • 2016 International Congress

    A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

    L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

    Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley